No Data
Scotiabank Initiates Coverage On PTC Therapeutics With Sector Perform Rating, Announces Price Target of $55
PTC Therapeutics Coverage Assumed by Morgan Stanley at Overweight
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $70
Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $70
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)
Director Cashes Out on PTC Therapeutics Stock!
